Pharma major Lupin has received tentative approval for its Abacavir Sulfate (600 mg/300 mg) and Lamivudine tablets from the USFDA to market a generic version of ViiV Healthcare Company’s Epzicom tablets.
Epzicom tablets had US sales of $426 million. Lupin holds global leadership position in the anti-TB segment.